- Deutsche's Robyn Karnauskas weighs in on what, quite frankly, has been a nightmarish day for Sarepta Therapeutics (SRPT -63.4%).
- Karnauskas is now modeling a 2016 launch for eteplirsen. "Every 1 year delay impacts the DCF by $10/share," the analyst notes.
- Needham's Chad Messer is also out with some commentary, saying that while he "continues to believe in the efficacy and safety of eteplirsen, [he is] downgrading [the] shares to Hold [after losing] visibility to the regulatory hurdles for approval."
at Zacks.com (Nov 13, 2014)